SPOTLIGHT: FDA accepts BioDelivery drug app

The FDA has accepted BioDelivery Sciences International's new drug application for its nausea and vomiting treatment, Emezine. The FDA now has about nine months to decide whether to approve the product. If it receives the FDA's blessing, Emezine would be the BioDelivery's first drug to hit the market. The company licensed the drug from Reckitt Benckiser Healthcare. Report